We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros Biostructures Announces Collaboration with UCB
News

Proteros Biostructures Announces Collaboration with UCB

Proteros Biostructures Announces Collaboration with UCB
News

Proteros Biostructures Announces Collaboration with UCB

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Biostructures Announces Collaboration with UCB"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros biostructures GmbH has announced it has signed a research services agreement with UCB (Brussels, Belgium) where Proteros will support the structure-based discovery of small molecule drugs.

In the initial stage of the programme, Proteros will leverage its expertise in gene-to-structure projects and its proprietary technologies to solve the three dimensional structure of an undisclosed target together with its related proteins.
After the establishment of these crystallography systems, Proteros will screen fragments and compounds supplied by UCB with the objective of solving high resolution X-ray structures of the fragments and compounds to confirm the binding modes to the proteins, and therefore facilitating the medicinal chemistry and optimization of small molecules.

Dr. Torsten Neuefeind, Proteros’ Chief Executive Officer, commented: “We are very pleased to extend our successful relationship which we first entered in 2007, and now to be considered a key partner for UCB in this important project with UCB New Medicines™.”

The financial terms of the fixed research fees and milestones are not disclosed.
Advertisement